Many industrial innovative products are coming soon
COVID-19 antibody detection reagent and many other products go out of China and enter the international market
Expanded R&D team and introduced new R&D technology
Realized whole-line cold chain logistics for the first time nationwide
Completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, HIV, etc.
Be recognized as provincial level innovation and industrialization demonstration enterprise for several times
Established "Guangdong Postdoctoral Innovation Practice Base"
Be approved as a national “Post-Doctoral Research Center”
Established Suzhou R&D center
Moved into the new industrial park with a floor area of 23,000 m2
Cooperated with many international IVD enterprises, such as Unipath, Fujirebro, Siemens, MP, etc.
The market share of AIDS confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,Many self-developed products occupied over 60% of the market share.Many products became reference methods for disease detection, such as MYCOII and TP.PA.
1989, the first subsidiary of Livzon Pharmaceutical Group Inc.
Obtained pharmaceutical manufacturing license
Many products were successfully developed and marketed, including HBV, HIV, HCV ELISA reagents
麗珠試劑官方
麗珠試劑資訊
粵公網安備 44049002000690號
Technical Support:E-net